Xilio net loss narrows to $6.4 million in Q2 FY26; revenue more than doubles to $18.7 million - XLO News | RalliesXilio net loss narrows to $6.4 million in Q2 FY26; revenue more than doubles to $18.7 million
X
XLO• Program update
- The FDA cleared the IND for XTX501; Phase 1 dosing is expected in H2 2026, with initial NSCLC data slated for H2 2027.
Q2 financial results
- Xilio posted a Q2 net loss of $6.4 million, narrowing from a $15.8 million loss a year earlier.
- Revenue more than doubled to $18.7 million, driven by higher recognition under AbbVie and Gilead agreements.
- R&D expenses dipped to $14.6 million; G&A costs climbed to $7.6 million on higher personnel-related costs.
Cash position and outlook
- Cash and cash equivalents totaled $136 million as of June 30, 2026; runway projected into Q1 2028.
•
